<DOC>
	<DOCNO>NCT01451827</DOCNO>
	<brief_summary>The purpose study compare short-term effect two tolvaptan formulation patient ADPKD .</brief_summary>
	<brief_title>8-Week Study Tolvaptan Dose Forms Autosomal Dominant Polycystic Kidney Disease ( ADPKD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Age 18 50 2 . Subjects : BMI 19 35 kg/m2 diagnosis ADPKD modify Ravine criterion : family history : 3cysts/kidney sonography 5 CT MRI Without family history : 10 cyst per kidney eGFR &gt; 45 mL/min/1.73 m2 CKDEPI equation 3 . Subjects plan become pregnant willing comply birth control requirement . 4 . Subjects must good health determine screen test . 5 . Subjects provide informed consent able comply trial requirement . 1 . Subjects use diuretic within 14 day prior randomization , requirement intermittent constant diuretic use reason 2 . Subjects eGFR &lt; 45 mL/min/1.73 m2 calculate base recent historical creatinine last 12 month 3 . Subjects : incontinence , overactive bladder , urinary retention ( eg , BPH ) , mean subject symptoms frequent nocturia , determine medical history urinary urgency carefully evaluate exclude nonADPKD GU issue prior entry . liver disease , liver function abnormality , serology expect ADPKD cystic liver disease baseline history renal surgery cyst drainage within 6 month randomization blood pressure 150/95 mmHg &lt; 90/40 mmHg . heart rate outside range 40 90 bpm . advanced diabetes history poor control , evidence significant renal disease renal cancer , single kidney , recent renal surgery significant medical history may interfere study objective significant abnormality serum sodium concentration ( &lt; 135 &gt; 145 mEq/L ) history drug and/or alcohol abuse within 2 year prior screen clinically significant allergic reaction tolvaptan chemically related structure benzazepines ( eg , benzazepril , conivaptan , fenoldopam mesylate , mirtazapine ) 4 . Subjects take investigational drug within 30 day precede randomization Day 0 5 . Subjects take medication concomitant illnesses likely confound endpoint assessment , include take approve ( ie , market ) therapy purpose affect PKD cyst tolvaptan , somatostatin agonist ( ie , octreotide , sandostatin ) , Rapamune ( sirolimus ) , antisense RNA therapy , vasopressin antagonist ( eg , OPC31260 [ mozavaptan ] VaprisolÂ® [ conivaptan ] ) agonists ( eg , desmopressin ) , cyst reduction surgery 6 . Subjects antihypertensives antihypertensive regimen least 30 day prior first dose IMP 7 . Subjects contraindication , interference , MRI assessments 8 . Subjects history serious mental disorder , opinion investigator , would exclude subject participate trial 9 . Subjects previous exposure tolvaptan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Kidney Disease</keyword>
	<keyword>Polycystic Kidney Disease</keyword>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
	<keyword>PKD</keyword>
	<keyword>ADPKD</keyword>
</DOC>